DeuterOncology

Executive Summary

DeuterOncology is a Belgian clinical-stage biotechnology company founded in 2020, headquartered in Leuven with operations in Liège. The company specializes in developing deuterated small molecule kinase inhibitors, leveraging deuteration to enhance the pharmacokinetic and safety profiles of established drug scaffolds. Its lead program, DO-2, targets MET-driven cancers, a pathway implicated in multiple solid tumors. By replacing hydrogen with deuterium at key positions, DeuterOncology aims to improve metabolic stability, reduce toxic metabolite formation, and prolong drug exposure, potentially offering best-in-class alternatives to existing MET inhibitors. The company's approach addresses a significant unmet need in cancers with MET amplifications or mutations, including non-small cell lung cancer and gastric cancer. As a private, pre-clinical entity, DeuterOncology is poised to advance DO-2 toward clinical development, with a focus on generating robust preclinical data to support an IND filing. The company's innovative deuteration platform and focused pipeline position it as a promising player in the targeted oncology space.

Upcoming Catalysts (preview)

• H2 2026IND submission for DO-240% success
• Q3 2026Preclinical efficacy data publication70% success
• TBDSeries A financing round50% success